54087-03-5

Basic information

• Product Name: 6-Chloropyridine-2-carbaldehyde
• Synonyms: 6-Chloropyridine-2-carbaldehyde;6-Chloropicolinaldehyde;6-chloro-2-pyridinecarbaldehyde;6--Chloro-2-pyridinecarboxaldehyde;6-chloropyridine-2-carboxaldehyde;2-Chloro-6-formylpyridine, 6-Chloropicolinaldehyde
• CAS NO: 54087-03-5
• Molecular Formula: C₆H₄ClNO
• Molecular Weight: 141.56
• Mol File: 54087-03-5.mol

Chemical Properties

• Melting Point: 68-69°
• Boiling Point: 218.969 °C at 760 mmHg
• Flash Point: 86.229 °C
• Appearance: White/Powder
• Density: 1.332 g/cm³
• Vapor Pressure: 0.122mmHg at 25°C
• Refractive Index: 1.593
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 1.00±0.10(Predicted)
• CAS DataBase Reference: 6-Chloropyridine-2-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloropyridine-2-carbaldehyde(54087-03-5)
• EPA Substance Registry System: 6-Chloropyridine-2-carbaldehyde(54087-03-5)

Safety Data

• Statements: 43
• Safety Statements: 36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 54087-03-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C6H4ClNO/c7-6-3-1-2-5(4-9)8-6/h1-4H

Upstream product

• 33674-97-4 6-chloro-2-pyridinemethanol 
• 109-09-1 2-chloropyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 2591-86-8 N-Formylpiperidine 
• 18368-63-3 6-chloro-2-picoline 
• 52313-59-4 2-Chloro-6-methylpyridine N-oxide 
• 86209-84-9 2-acetoxymethyl-6-chloropyridine 
• 4684-94-0 6-chloropicolinic acid 
• 258506-66-0 2-chloro-5-iodo-pyridine 
• 33252-29-8 6-chloro-pyridine-2-carbonitrile 

Downstream Products

• 108337-79-7 2,6-dimethyl-4-(6-chloro-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester 
• 1026587-36-9 2-chloro-6-(difluoromethyl)pyridine 
• 1421236-76-1 (R)-N-((1R,2R)-3-((S)-4-benzyl-5,5-dimethyl-2-oxooxazolidin-3-yl)-1-(6-chloropyridin-2-yl)-2-methyl-3-oxopropyl)-2-methylpropane-2-sulfinamide 
• 1352067-74-3 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(6-chloropyridin-2-yl)propyl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 

Relevant articles and documents

Method for preparing aldehyde and acid by electrochemical dehydrochlorination of polychloromethylpyridine derivatives

The invention discloses a method for preparing aldehyde and an acid by electrochemical dechlorination of a polychloromethylpyridine derivative, the method comprises the following steps: dissolving thepolychloromethylpyridine derivative in an acetic acid and acetate- containing buffer solution to obtain an electrolytic reaction solution; taking the electrolytic reaction solution as a cathode liquid, performing electrolytic reduction dechlorination reaction at a cathode, and hydrolyzing in the solution to obtain a polychlorinated pyridylaldehyde or acid derivative. The polychloromethylpyridinederivative is shown in formula (I), and the product polychlorinated pyridylaldehyde or acid derivative is shown in formula (II): in the formula (I), m is 0, 1, 2, 3 or 4, n is 0 or 1, and R' is an easy-to-oxidize or easy-to-hydrolyze substituent. The m and the R' in the formula (II) are same as that in the formula (I), R is H or OH, no waste acid is generated in the preparation process, the easy-to-oxidize or easy-to-hydrolyze substituent contained in the polychloromethylpyridine derivative and carbon-chlorine bonds on pyridine rings are not affected, and the recovery conversion rate is high.

NOVEL OXALYL PIPERAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

Diastereoselective organocatalytic Mannich access to azacyclic system en route to lyconadin A

Organocatalytic and stereoselective Mannich coupling of hindered and chiral cyclohexylcarboxaldehyde is described for a synthetic approach to the pyrrolidine core of lyconadin A. The strategy led concisely and stereoselectively to complex azaheterocyclic system containing up to five stereocenters.

TMSCH2Li-LiDMAE: a new nonnucleophilic reagent for C-2 lithiation of halopyridines

A new superbasic reagent has been discovered by combining TMSCH2Li and LiDMAE in hexane. This reagent was found highly efficient for the C-2 lithiation of sensitive chloro- and fluoropyridines. The metallation occurred chemo- and regioselectively at 0 °C avoiding the nucleophilic addition or substrate degradation commonly obtained with other alkyllithiums even at lower temperatures.

IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS

Compounds of Formula (I) are provided, as are methods for their preparation. The variables Z1, Z2, Z3,R4, R5, R6, R7, R8 and Ar in the above formula are defined

Unusual C-6 lithiation of 2-chloropyridine-mediated by BuLi-Me2N(CH2)2OLi. New access to 6-functional-2-chloropyridines and chloro-bis-heterocycles

Formula Presented The reaction of 2-chloropyridine with alkylithium generally results in nucleophilic addition leading to the loss of chlorine atom while exclusive directed ortho metalation is obtained using LDA. Herein it is shown that the BuLi-Me2

Synthesis, rotamer orientation, and calcium channel modulation activities of alkyl and 2-phenethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(3- or 6-substituted-2-pyridyl)-5-pyridinecarboxylates

A group of racemic alkyl and 2-phenethyl 1,4-dihydro-2,6-dimethyl-3- nitro-4-(3- or 6-substituted-2-pyridyl)-5-pyridinecarboxylates (13a-q) was prepared using a modified Hantzsch reaction that involved the condensation of a 3- or 6-substituted-2-pyridinecarboxaldehyde (7a-j) with an alkyl or 2- phenethyl 3-aminocrotonate (11a-d) and nitroacetone (12). Nuclear Overhauser (NOE) studies indicated there is a significant rotamer fraction in solution where the pyridyl nitrogen is oriented above the 1,4-dihydropyridine ring, irrespective of whether a substituent is located at the 3- or 6-position. A potential H-bonding interaction between the pyridyl nitrogen free electron pair and the suitably positioned 1,4-dihydropyridine NH moiety may stablize this rotamer orientation. In vitro calcium channel antagonist and agonist activities were determined using guinea pig ileum longitudinal smooth muscle (GPILSM) and guinea pig left atrium (GPLA) assays, respectively. Compounds having an i-Pr ester substituent acted as dual cardioselective calcium channel agonists (GPLA)/smooth muscle-selective calcium channel antagonists (GPILSM), except for the C-4 3-nitro-2-pyridyl compound which exhibited an antagonist effect on both GPLA and GPILSM. In contrast, the compounds with a phenethyl ester group, which exhibited antagonist activity (IC50 = 10-5- 10-7 M range) on GPILSM, were devoid of cardiac agonist activity on GPLA. Structure-activity relationships showing the effect of a substituent (Me, CF3, C1, NO2, Ph) at the 3- or 6-position of a C-4 2-pyridyl moiety and a variety of ester substituents (Me, Et, i-Pr, PhCH2CH2-) upon calcium channel modulation are described. Compounds possessing a 3- or 6-substituted- 2-pyridyl moiety, in conjuction with an i-Pr ester substituent, are novel 1,4-dihydropyridine calcium channel modulators that offer a new drug design approach directed to the treatment of congestive heart failure and may also be useful as probes to study the structure-function relationships of calcium channels.

Heteroarylethanol-pyridylalkylamines for controlling animal growth

A compound for promoting livestock production and for controlling obesity in humans and animals, of the formula STR1 in which A represents =CH-- or =N--, R0 represents hydrogen or methyl, R1 and R3 each independently represents hydrogen, hydroxyl, halogen, cyano, alkyl, halogenoalkyl, hydroxyalkyl, alkoxycarbonyl, aminocarbonyl, mono- and dialkylaminocarbonyl, alkoxy, halogenoalkoxy, halogenoalkylthio, NHSO2 -alkyl, R2 represents hydrogen, hydroxyl, alkoxy or the radical --NR5 R6, R4 represents hydrogen, C1 -C10 -alkyl which is optionally substituted by hydroxyl, halogen, alkoxy, acyloxy or the radical --NH7 R8, or represents the radical COR9 or the radical --O--Z--R10, Z represents C1 -C10 -alkylene, -alkenylene or alkynylene, R5 represents hydrogen or alkyl, R6 represents hydrogen, alkyl, halogenoalkyl or acyl, or R5 and R6 together with the adjoining N atom form a saturated or unsaturated heterocyclic 4-, 5- or 6-membered ring, R7 and R8 each independently represents hydrogen, optionally substituted alkyl, optionally substituted aryl, R9 represents hydroxyl, alkoxy or the radical --NR7 R8, R10 represents hydroxyl, alkoxy, acyloxy, optionally substituted aryloxy or aralkyloxy, with the substituent R4 and the alkylamino group in the pyridyl ring of the formula I being in the p position with respect to one another, or a physiologically tolerated salt thereof, or, if A represents nitrogen, optionally the N-oxide thereof.

Substituted 2-acylpyridine-α-(N)-hetarlyhydrazones and medicaments containing the same

Substituted 2-acylpyridine-α-(N)-hetarylhydrazones are described, which are suitable as active substances for the treatment of antimicrobial and in particular antimycobacterial diseases, as well as active substances for the treatment of malaria or malignant tumours. The compounds have a marked synergistic activity combined with inhibitors of folate synthase, dihydrofolic acid reductase, DNA-synthesis and RNA-synthesis.